PreveCeutical Medical (TSE:PREV) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PreveCeutical Medical’s subsidiary, BioGene Therapeutics, has appointed Stephen Glover to its Board of Directors, leveraging his extensive leadership experience in the biopharma industry to advance their mission of developing groundbreaking therapies. Glover, known for his successful track record in corporate strategy and financial management, is expected to significantly contribute to the company’s growth and innovation.
For further insights into TSE:PREV stock, check out TipRanks’ Stock Analysis page.